Key Details
Price
$59.75Last Dividend
$0.05Annual Revenue
$2.96 BAnnual EPS
$2.90Annual ROE
33.57%Beta
1.02Events Calendar
Next earnings date:
Feb 13, 2025Recent quarterly earnings:
Nov 05, 2024Recent annual earnings:
Feb 13, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Dec 02, 2024Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Bruker's latest technology, EpicIF, aims to improve the CellScape Precise Spatial Proteomics platform.
Bruker experienced strong revenue growth in the third quarter, even though the overall market conditions were weak.
Biognosys has announced that it will take part in the 23rd Human Proteome Organization (HUPO) World Congress, which will be held in Dresden, Germany, from October 20 to October 24.
Bruker's strong growth potential in its Nano segment is promising. However, negative changes in currency exchange rates may create difficulties.
Dublin, Sept. 20, 2024 (GLOBE NEWSWIRE) -- ResearchAndMarkets.com has released a new report titled "Dermatology Diagnostic Devices Market (2024 Edition)," which analyzes the market by device type, application, end-user, and region, providing insights and forecasts from 2020 to 2030. The report covers the growth of the Global Dermatology Diagnostic Devices market, which grew at a compound annual growth rate (CAGR) of 10.29% from 2020 to 2023, reaching a value of USD 7.57 billion in 2023. It is projected that the market will grow to USD 17.65 billion by 2030.
Bruker (BRKR) shared its earnings report 30 days ago. What can we expect for the stock moving forward?
BRKR shows strong growth potential in its key areas, which is promising. However, economic issues and competition may create difficulties.
Biognosys has partnered with Alamar Biosciences to offer NULISA multiplex assay services for biopharma research. Their NULISAseq™ CNS Disease and Inflammation panels are now available as a contract research service from their advanced proteomics facility in Europe. This combination of NULISA assays and TrueDiscovery® mass spectrometry provides comprehensive solutions for plasma proteomics, making Biognosys a leader in next-generation proteomics for drug discovery and development.
Bruker (BRKR) has set up the 1.2 GHz Avance NMR Spectrometer at KBSI, which will help in making important scientific discoveries.
Assess Bruker's (BRKR) dependence on international sales to gain insights into the company's financial health, opportunities for growth, and possible stock price trends.
FAQ
- What is the primary business of Bruker?
- What is the ticker symbol for Bruker?
- Does Bruker pay dividends?
- What sector is Bruker in?
- What industry is Bruker in?
- What country is Bruker based in?
- When did Bruker go public?
- Is Bruker in the S&P 500?
- Is Bruker in the NASDAQ 100?
- Is Bruker in the Dow Jones?
- When was Bruker's last earnings report?
- When does Bruker report earnings?
- Should I buy Bruker stock now?